Margaux Duchamp (EPFL 2021)
ArcoScreen
Today, 35% of all marketed drugs act on the same family of proteins. These proteins hold great promise for the treatment of diseases such as Alzheimer’s and many cancers.
The current methods used to discover new drugs active on these proteins are based on cell models dissimilar to patient cells, drastically increasing the risk of failure in clinical trials.
Our patented ArcoFlow solution revolutionises drug discovery by directly testing the effect of a molecule on patient cells, thus enabling safer drugs to be brought to market quickly. ArcoFlow is the only automated, microfluidic test that identifies drugs active on this family of proteins directly on diseased patient cells.
ArcoScreen distributes its ArcoFlow technology as a service and as consumable kits for pharmaceutical companies.